Vera Therapeutics (VERA) priced its newly approved Trutakna at about $425,000 annually, above Wedbush's expectations, as the drug is expected to become available within three to four weeks, the brokerage said in a note Wednesday.

Wedbush also said the pricing "appears to be a premium" to Otsuka's Voyxact.

"Where we have more concern is on the commercialization activities and how Trutakna will be positioned versus other monthly APRIL-targeted therapies," the brokerage said.

Wedbush maintained its neutral rating and raised its price target to $43 from $35.

Price: 41.44, Change: -1.52, Percent Change: -3.54